Show simple item record

dc.contributor.authorSternberg, Cen_GB
dc.contributor.authorHawkins, Robert Een_GB
dc.contributor.authorWagstaff, Jen_GB
dc.contributor.authorSalman, Pen_GB
dc.contributor.authorMardiak, Jen_GB
dc.contributor.authorBarrios, Cen_GB
dc.contributor.authorZarba, Jen_GB
dc.contributor.authorGladkov, Oen_GB
dc.contributor.authorLee, Een_GB
dc.contributor.authorSzczylik, Cen_GB
dc.contributor.authorMcCann, Len_GB
dc.contributor.authorRubin, Sen_GB
dc.contributor.authorChen, Men_GB
dc.contributor.authorDavis, Ien_GB
dc.date.accessioned2013-05-20T12:42:38Z
dc.date.available2013-05-20T12:42:38Z
dc.date.issued2013-04
dc.identifier.citationA randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. 2013, 49 (6):1287-96 Eur J Canceren_GB
dc.identifier.issn1879-0852
dc.identifier.pmid23321547
dc.identifier.doi10.1016/j.ejca.2012.12.010
dc.identifier.urihttp://hdl.handle.net/10541/292373
dc.description.abstractIn this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer (Oxford, England : 1990)en_GB
dc.titleA randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. Electronic address: cstern@mclink.it.en_GB
dc.identifier.journalEuropean Journal of Canceren_GB
html.description.abstractIn this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported.


Files in this item

This item appears in the following Collection(s)

Show simple item record